Komori
Share Issuance and Disposal4882Perseus Proteomics Inc.Pharmaceuticals

Notice regarding the issuance of the 31st series of stock acquisition rights through a third-party allotment (with an exercise price adjustment clause) and execution of a stock acquisition rights purchase agreement

The company resolved to issue 46,000 units of the 31st series of stock acquisition rights, with Macquarie Bank Limited as the allottee. The exercise price will be adjusted in line with the share price. If all rights are exercised, up to 4.60 million new shares will be issued and approximately ¥460 million will be raised.

Worth reading
88Important
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Mixed performance
Direction inferred from the company’s description.
Scale
24.96
Dilution rate (%)
Wording
Conditional
How definitive the wording is.

Details of issuance or disposal

Issuance of the 31st series of stock acquisition rights through a third-party allotment (with an exercise price adjustment clause)

Who receives how much

4,600,000 potential shares (46,000 stock acquisition rights, each exercisable for 100 shares)

Macquarie Bank Limited4,600,000 potential shares

The lower thin line represents the existing number of shares to which these shares will be added.

¥29 per stock acquisition right
Total issue value

¥1,334,000

Amount of funds to be raised
Total payment amount of ¥470,534,000; estimated net proceeds of ¥459,534,000
Estimated issuance expenses
¥11,000,000
Specific use of funds
Research and development funding for PPMX-T004Amount ¥70 million / Scheduled timing of expenditures July 2027 to March 2029
Funding for development of the drug discovery pipelineAmount ¥280 million / Scheduled timing of expenditures July 2027 to March 2029
Funding for development of AI-hybrid drug discoveryAmount ¥50 million / Scheduled timing of expenditures July 2027 to March 2029
Working capitalAmount ¥59 million / Scheduled timing of expenditures July 2027 to March 2029
Existing Shares and Increase
+24.96%Rate of increase
18,429,500 shares23,029,500Shares

24.96% (24.98% based on voting rights)

The dilution rate shows what proportion the newly issued shares represent of the existing shares. The higher the proportion, the more the value and voting rights per share are diluted.

Terms of the stock acquisition rights
Exercise price
Initially ¥102. Adjusted to 92% of the closing price on the trading day preceding each adjustment date. Floor of ¥56. If exercise exceeds the prescribed limit, the exercise price may not be below the closing price on the date of the issuance resolution.
Exercise period
9 December 2026 to 8 December 2028
Number of Stock Acquisition Rights
Total issuance of 46,000 units. The number of unexercised rights is Not disclosed.
Conditions on transfer restrictions

Restricted stock is stock awarded as compensation that cannot be sold during a specified period, with the restrictions lifted once the applicable conditions are met.

Transfer restriction period
From the date of execution of this purchase agreement until the earliest of the expiration of the exercise period, completion of exercise of all rights, the date on which the company acquires all rights, or the date of termination of the agreement (subject to exceptions such as prior approval).
Conditions for lifting transfer restrictions
Prior approval by the company's board of directors is required, except for transfers to an affiliate of the prospective allottee.
Offering structure
Major shareholders after the offering
The prospective allottee has not committed to long-term ownership, and no post-offering ownership percentage is disclosed.
Intended allottee's holding policy
For pure investment purposes. The common shares acquired through exercise will be sold within a relatively short period, as appropriate based on the allottee's judgment. The stock acquisition rights themselves are not scheduled to be transferred.
Payment date
8 December 2026
Basis for determining the amount to be paid
Valued by an independent third-party valuation institution using a Monte Carlo simulation. The payment amount for the stock acquisition rights is ¥29 per right, equal to the valuation. The initial exercise price of ¥102 is 92% of the closing price of ¥111 on 19 November 2026.
Procedures under the Corporate Code of Conduct
Because the dilution rate is below 25% and the transaction does not involve a change in the controlling shareholder, obtaining an opinion from an independent third party and conducting procedures to confirm shareholders' intentions are not required.
Most recent equity financing
Timing 7 March 2024 / Type 28th series of stock acquisition rights through a third-party allotment / Amount Planned proceeds of ¥1,543,966,000 (estimated net proceeds), Timing 5 January 2026 / Type 29th series of stock acquisition rights through a third-party allotment / Amount Planned proceeds of ¥930,380,800 (estimated net proceeds of ¥705 million)
Impact on Business Performance
The impact on results for the fiscal year ending March 2027 will be immaterial, and there will be no changes to the earnings forecast.
Details of issuance or disposal
ItemDetails
Type of issuance or disposalIssuance of the 31st series of stock acquisition rights through a third-party allotment (with an exercise price adjustment clause)
Number of shares to be issued or disposed of4,600,000 potential shares (46,000 stock acquisition rights, each exercisable for 100 shares)
Issue price and disposal price¥29 per stock acquisition right
Total issue value¥1,334,000
Amount of funds to be raisedTotal payment amount of ¥470,534,000; estimated net proceeds of ¥459,534,000
Estimated issuance expenses¥11,000,000
Specific use of fundsDetails Research and development funding for PPMX-T004 / Amount ¥70 million / Scheduled timing of expenditures July 2027 to March 2029, Details Funding for development of the drug discovery pipeline / Amount ¥280 million / Scheduled timing of expenditures July 2027 to March 2029, Details Funding for development of AI-hybrid drug discovery / Amount ¥50 million / Scheduled timing of expenditures July 2027 to March 2029, Details Working capital / Amount ¥59 million / Scheduled timing of expenditures July 2027 to March 2029
Payment date8 December 2026
Intended allotteeName Macquarie Bank Limited / Number of Shares 4,600,000 potential shares
Intended allottee's holding policyFor pure investment purposes. The common shares acquired through exercise will be sold within a relatively short period, as appropriate based on the allottee's judgment. The stock acquisition rights themselves are not scheduled to be transferred.
Dilution Rate24.96% (24.98% based on voting rights)
Total number of issued shares18,429,500 shares → 23,029,500 shares (if all rights are exercised)(24.96%)
Basis for determining the amount to be paidValued by an independent third-party valuation institution using a Monte Carlo simulation. The payment amount for the stock acquisition rights is ¥29 per right, equal to the valuation. The initial exercise price of ¥102 is 92% of the closing price of ¥111 on 19 November 2026.
Exercise priceInitially ¥102. Adjusted to 92% of the closing price on the trading day preceding each adjustment date. Floor of ¥56. If exercise exceeds the prescribed limit, the exercise price may not be below the closing price on the date of the issuance resolution.
Exercise period9 December 2026 to 8 December 2028
Number of Stock Acquisition RightsTotal issuance of 46,000 units. The number of unexercised rights is Not disclosed.
Transfer restriction periodFrom the date of execution of this purchase agreement until the earliest of the expiration of the exercise period, completion of exercise of all rights, the date on which the company acquires all rights, or the date of termination of the agreement (subject to exceptions such as prior approval).
Conditions for lifting transfer restrictionsPrior approval by the company's board of directors is required, except for transfers to an affiliate of the prospective allottee.
Procedures under the Corporate Code of ConductBecause the dilution rate is below 25% and the transaction does not involve a change in the controlling shareholder, obtaining an opinion from an independent third party and conducting procedures to confirm shareholders' intentions are not required.
Most recent equity financingTiming 7 March 2024 / Type 28th series of stock acquisition rights through a third-party allotment / Amount Planned proceeds of ¥1,543,966,000 (estimated net proceeds), Timing 5 January 2026 / Type 29th series of stock acquisition rights through a third-party allotment / Amount Planned proceeds of ¥930,380,800 (estimated net proceeds of ¥705 million)
Major shareholders after the offeringThe prospective allottee has not committed to long-term ownership, and no post-offering ownership percentage is disclosed.
Impact on Business PerformanceThe impact on results for the fiscal year ending March 2027 will be immaterial, and there will be no changes to the earnings forecast.
Items this document does not state (6)
Reason for acquisition without considerationCategories and Number of Persons CoveredTotal Stock-Based CompensationUnderwriter / lead underwriterOverallotmentStock Split Ratio

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To raise research and development funding for PPMX-T004, the drug discovery pipeline and AI-hybrid drug discovery, as well as working capital. The company cited the fact that funds raised through the 29th series of stock acquisition rights fell short of the initial estimate and its determination that additional funding was needed for new drug discovery projects and AI-hybrid drug discovery.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.